212 related articles for article (PubMed ID: 33351823)
1. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.
Kruik-Kollöffel WJ; van der Palen J; Doggen CJM; van Maaren MC; Kruik HJ; Heintjes EM; Movig KLL; Linssen GCM
PLoS One; 2020; 15(12):e0244231. PubMed ID: 33351823
[TBL] [Abstract][Full Text] [Related]
2. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
4. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
5. Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study.
Bitar S; Thilly N; Agrinier N
Eur J Clin Pharmacol; 2021 Oct; 77(10):1569-1581. PubMed ID: 33970296
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.
Sanam K; Bhatia V; Bajaj NS; Gaba S; Morgan CJ; Fonarow GC; Butler J; Deedwania P; Prabhu SD; Wu WC; White M; Love TE; Aronow WS; Fletcher RD; Allman RM; Ahmed A
Am J Med; 2016 Oct; 129(10):1067-73. PubMed ID: 27262781
[TBL] [Abstract][Full Text] [Related]
7. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y
Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488
[TBL] [Abstract][Full Text] [Related]
8. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
[TBL] [Abstract][Full Text] [Related]
10. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
[TBL] [Abstract][Full Text] [Related]
11. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
[TBL] [Abstract][Full Text] [Related]
12. Impact of clinical characteristics and management on the prognosis of unselected heart failure patients.
Eschalier R; Chenaf C; Mulliez A; Yalioua A; Clerfond G; Authier N; Vorilhon C; Citron B; Pereira B; Jean F; Souteyrand G; Motreff P; Eschalier A; Lusson JR
Cardiovasc Drugs Ther; 2015 Feb; 29(1):89-98. PubMed ID: 25700624
[TBL] [Abstract][Full Text] [Related]
13. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
[TBL] [Abstract][Full Text] [Related]
15. Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015.
Kruik-Kollöffel WJ; Linssen GCM; Kruik HJ; Movig KLL; Heintjes EM; van der Palen J
Heart Fail Rev; 2019 Jul; 24(4):499-510. PubMed ID: 30848404
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent association of discharge heart-failure medications with clinical outcomes in a super-aged society.
Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
Biomed Pharmacother; 2022 Nov; 155():113761. PubMed ID: 36271549
[TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020.
Ødegaard KM; Lirhus SS; Melberg HO; Hallén J; Halvorsen S
ESC Heart Fail; 2023 Feb; 10(1):405-415. PubMed ID: 36266969
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany.
Michel A; Lecomte C; Ohlmeier C; Raad H; Basedow F; Haeckl D; Beier D; Evers T
Am J Cardiovasc Drugs; 2024 May; 24(3):409-418. PubMed ID: 38573461
[TBL] [Abstract][Full Text] [Related]
19. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
[TBL] [Abstract][Full Text] [Related]
20. Heart failure medications prescribed at discharge for patients with left ventricular assist devices.
Shreibati JB; Sheng S; Fonarow GC; DeVore AD; Yancy CW; Bhatt DL; Schulte P; Peterson ED; Hernandez A; Heidenreich PA
Am Heart J; 2016 Sep; 179():99-106. PubMed ID: 27595684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
